NCT07108595View on ClinicalTrials.gov

Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study

CompletedOBSERVATIONAL

Enrollment

142

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2024

Conditions

Breast Cancer

Interventions

DRUG

T- Dxd

T-DXd based therapy

Trial Locations (1)

Unknown

Jiangsu Provincial People's Hospital, Nanjing, JiangSu 210000, Nanjing

All Listed Sponsors

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER

NCT07108595 - Efficacy and Safety of T-DXd in Patients With HER2-positive and HER2-low Metastatic Breast Cancer: a Real-world Study | Biotech Hunter | Biotech Hunter